42 results about "V region" patented technology

The invention provides for a polyvalent protein complex (PPC) comprising two polypeptide chains generally arranged laterally to one another. Each polypeptide chain typically comprises 3 or 4 “v-regions”, which comprise amino acid sequences capable of forming an antigen binding site when matched with a corresponding v-region on the opposite polypeptide chain. Up to about 6 “v-regions” can be used on each polypeptide chain. The v-regions of each polypeptide chain are connected linearly to one another and may be connected by interspersed linking regions. When arranged in the form of the PPC, the v-regions on each polypeptide chain form individual antigen binding sites.

A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRS, and mouse H chain CDRs of a monoclonal antibody to the IL-6R. Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses.

A reshaped antibody comprising: (A) L chains comprising: (1) a human C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of a mouse monoclonal antibody; and (B) H chains comprising: (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRs, and H chain CDRs of a mouse monoclonal antibody to human IL-6. Since the major portions of the reshaped human antibody are derived from human, and the mouse CDRs are less immunogenic, then the present reshaped human antibody is less immunogenic, and therefore inhibits information transfer by IL-6, and is promising as a therapeutic agent for diseases caused by IL-6.

The invention provides a method for carrying out high-throughput sequencing on a TCR (T cell receptor) or a BCR (B cell receptor). The method is characterized by designing upstream primers according to gene features of a V region of the TCR or the BCR and designing downstream primers according to gene features of a C region or a J region of the TCR or the BCR and obtaining sequences of the of the TCR or the BCR in combination with the multiplex PCR (polymerase chain reaction) technology and high-throughput sequencing, thus analyzing the rearrangement information of the TCR or the BCR. Compared with 25-30 cycles of existing multiplex PCR, two cycles of the multiplex PCR technology provided by the invention can conduce to greatly reducing the sequencing errors caused by primer amplification preference. Besides, the invention also provides a method for correcting multiplex PCR (polymerase chain reaction) primer deviation by utilizing DNA (deoxyribonucleic acid) tag sequences, thus further reducing the sequencing errors caused by primer amplification preference and intrinsic sequencing errors of high-throughput sequencing.

The present invention relates to primer compositions for the amplification of T cell receptor beta chain CDR3 coding sequences and uses of the primer compositions. The primer compositions for the amplification of T cell receptor beta chain CDR3 coding sequence comprises: a first primer group which consists of at least one V region primers, and each of the at least one V region primers all comprises a sequence complementary to at least one V gene fragment; and a second primer group, which consists of at least one J region primers, and each of the at least one J region primers all comprises a sequence complementary to at least one J gene fragment. By using the primer compositions, the T cell receptor beta chain CDR3 coding sequences can be effectively enriched, thus providing a convenient tool for the in-depth study of the T cell receptor beta chain CDR3.

The present invention is a method of producing a P(phosphorus)-doped silicon single crystal by Czochralski method, wherein, at least, a growth of the single crystal is performed so that an Al (aluminum) concentration is 2×10¹² atoms/cc or more. Thereby, there can be provided a method of easily and inexpensively producing a P(phosphorus)-doped silicon single crystal of defect-free region having an excellent capability of electrical characteristics to be high breakdown voltage, which contains neither, for example, V region, OSF region, nor large dislocation cluster (LSEPD, LFPD) region.

The invention provides a primer group for developing a rhesus T cell immune repertoire, a high-flux sequencing method and application of method. The method comprises the following steps: setting 26 forward primer sequences in a variable region, namely a V region aiming at rhesus TCR; setting 13 reverse primer sequences in a joining region, namely a J region aiming at TCR; performing multiple PCR amplification on the TCR sequence with the magnitude order of about 10<7> in peripheral blood or other immunologic tissues, preparing a high-flux sequencing library, sequencing, and performing comprehensive analysis on the rhesus TCR gene immune repertoire by virtue of bioinformatics. According to the technical scheme, the primer group has significance for constructing a rhesus analysis model, contributes to promoting the application of the rhesus model in research on autoimmune system diseases and infectious diseases and also contributes to deeply and widely recognizing the T cell mediated diseases by the humans.

The invention relates to the modification of antibodies reactive to human tumor necrosis factor alpha (TNF alpha) to result in anti-TNF alpha antibodies that are substantially non-immunogenic or less immunogenic than any non-modified parental antibody when used in vivo. The invention relates also to peptide molecules comprising T-cell epitopes of the V-regions of the parental antibody which are modified by amino acid alteration in order to reduce or eliminate said T-cell epitopes.

The present invention discloses a specific recognition sequence based T cell receptor high-throughput sequencing library construction and sequencing data analysis method. According to the method, a specific reverse transcription primer is designed for an mRNA sequence of a C region of a TCR constant region, cDNA is obtained by reverse transcription, and the 3' end of the cDNA is connected with a library construction linker with a specific recognition sequence; then the linker with the specific recognition sequence is added by using a splint connection method, and a TCR gene rearrangement sequence is amplified under the action of DNA polymerase by utilizing a gene specific primer with a tag; and finally a DNA library is added with a sequencing linker by PCR amplification to prepare a high-throughput sequencing library, and the high-throughput sequencing library is used for sequencing. The TCR gene diversity is comprehensively analyzed by bioinformatics, and a rearrangement rule of TCR genes including J region, D region and V region genes can be accurately obtained. The method is high in library construction efficiency, few in library construction step, low in required RNA initial quantity and low in library construction cost.

The present invention relates to a method for in vitro producing polynucleotides encoding human germline antibody V-regions. Also disclosed is a library of human germline antibody V-region genes.

The invention discloses a multiple primer group and a method for constructing a human B cell immune repertoire with the same on the basis of high-throughput sequencing and belongs to the field of molecular biological detection. The multiple primer group consists of a group of upstream primers and a group of downstream primers, and the upstream primers are formed by connecting a joint 1, a primer bar code 1, a sequencing primer 1 and specific primers V1-V18 designed for V regions (variable regions) in series; the downstream primers are formed by connecting a joint 2, a primer bar code 2, a sequencing primer 2 and specific primers Va, Vd, Ve, Vg and Vm designed for conserved sequences of gene C regions (constant regions) of IgA, IgD, IgE, IgG and IgM in series; sequences of the primer bar code 1 and the primer bar code 2 are different while the sequences of the sequencing primer 1 and the sequencing primer 2 are the same. By means of the method, a BCR (B cell receptor) immune repertoirecan be constructed on the basis of a DNA sample or an RNA sample, and diversity information of BCRs can be completely covered. The construction efficiency is high and the cost is low.

The invention belongs to the technical field of biology, and particularly relates to a variable region sequence library construction kit and a sequencing method of a variable region sequence. The variable region sequence library construction kit comprises a first primer group, primers of first connectors and a second primer group, the first primer group comprises first primers which specifically recognize all subtype coding sequences in a J region, each first primer comprises a nucleotide sequence, a proofreading random section and the first connector which are connected successively, the nucleotide sequences specifically recognize the coding sequences in the J region, the second primer group comprises successively connected second primers which specifically recognize all subtype coding sequences in a V region, and each second primer comprises a nucleotide sequence which specifically recognizes the coding sequences in the V region and a second connector. The variable region sequence library construction kit and the sequencing method of the variable region sequence are used for overcoming the technical defect that an existing TCR (T cell receptor) or BCR (B cell receptor) variable region sequence library construction technology is low in amplification efficiency, biased in amplification and prone to losing sequence information of a variable region sequence library.

The invention relates to a primer combination for amplifying alpha chain CDR3 (complementary determining region 3) coding sequences of a T cell receptor and a use of the primer combination. The primer combination comprises a first primer set comprising at least one V region primer each of which comprises a sequence complementary with at least one V gene segment, and a second primer set comprising at least one J region primer each of which comprises a sequence complementary with at least one J gene segment. By virtue of the primer combination, the alpha chain CDR3 coding sequences of the T cell receptor can be effectively enriched, so that a convenient tool is provided for in-depth study of the alpha chain CDR3 of the T cell receptor.

Disclosed herein are safe doses of dual-V-region antibody-like binding proteins or fragments thereof, as well as methods for assessing binding of dual-V-region antibody-like proteins or fragments thereof to their targets, and methods of treating idiopathic pulmonary fibrosis (IPF) by administering safe doses of dual-V-region antibody-like binding proteins or fragments thereof. In some embodiments, the dual-V-region antibody-like binding proteins or fragments thereof bind both IL-4 and IL-13.

The present invention relates inter alia to a rodent or rodent cell having a genome comprising: i) one or more companion animal IGH V region genes, one or more companion animal D region genes and one or more companion animal J region genes; and (ii) optionally one or more companion animal IGL kappa V region genes and one or more companion animal IGL kappa J region genes; and/or one or more companion animal IGL lambda V region genes and one or more companion animal IGL lambda J region genes, wherein the rodent or rodent cell is capable of expressing the companion animal variable region gene(s) to form an antibody chain and wherein the companion animal species is not a rodent.

The invention provides methods for treating Systemic Sclerosis by administering a dual-V region bispecific antibody that specifically binds IL-4 and IL-13.

The invention relates to a primer set used for amplifying immunoglobulin light-chain CDR3 sequences, a kit and methods thereof, a method for enriching the immunoglobulin light-chain CDR3 sequences, a method for constructing a sequencing library of the immunoglobulin light-chain CDR3 sequences, a method for determining the sequence information of the immunoglobulin light-chain CDR3 sequences, a method for determining individual immunization states, and a system for determining the individual immunization states. The primer set comprises: a forward primer group, wherein the forward primer group is composed of at least one V region primer, and each of the at least V region primer includes a sequence complementary with at least one V gene fragment; and a backward primer group, wherein the backward primer group is composed of at least one J region primer, and each of the at least J region primer includes a sequence complementary with at least one J gene fragment. The primer set can effectively enrich the immunoglobulin light-chain CDR3 sequences, so the primer set provides a convenient tool for deep-going researches on CDR3.

The present invention discloses reshaped antibody to human medulloblastoma cells comprising: (A) an L chain comprising: (1) a human L chain C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells; and, (B) an H chain containing: (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRs and H chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells. Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as medulloblastoma which strongly express antigen that is recognized by this antibody.